Ozempic vs Wegovy vs Mounjaro: Insurance Coverage Comparison
Ready to fight your denial? Generate your appeal letter in 5 minutes →
By AppealArmor | March 24, 2026 | 10 min read
GLP-1 receptor agonist medications have transformed diabetes and weight management treatment, but insurance coverage varies dramatically depending on which drug is prescribed, why it is prescribed, and which insurer you have. This guide compares coverage for the four most prescribed GLP-1 medications.
The Key Drugs at a Glance
| Drug | Active Ingredient | FDA Approval | List Price/mo |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | ~$935 |
| Wegovy | Semaglutide | Weight management | ~$1,350 |
| Mounjaro | Tirzepatide | Type 2 diabetes | ~$1,023 |
| Zepbound | Tirzepatide | Weight management | ~$1,060 |
Coverage Differences by Indication
The single biggest factor in coverage is the FDA-approved indication your doctor uses:
Type 2 Diabetes (Better Coverage)
Ozempic and Mounjaro are FDA-approved for diabetes. Most commercial insurers cover at least one GLP-1 for diabetes, though step therapy (trying metformin first) is nearly universal. Medicare Part D also covers these for diabetes.
Weight Management (Limited Coverage)
Wegovy and Zepbound are FDA-approved for weight loss. Many insurers explicitly exclude weight loss medications. Medicare Part D has historically not covered weight loss drugs, though this is changing with recent legislation.
Important
If your doctor prescribes Ozempic for weight loss (off-label), most insurers will deny it because Ozempic's FDA approval is only for diabetes. If weight management is the primary goal, your doctor should prescribe Wegovy (same active ingredient, approved for weight loss) or document the diabetes indication if applicable.
Coverage by Major Insurer
Coverage policies change frequently. As of early 2026, here are general patterns:
- UnitedHealthcare: Covers Ozempic and Mounjaro for diabetes with step therapy. Wegovy coverage varies by plan; many exclude it. Optum Rx formularies often prefer one GLP-1 over others.
- Aetna/CVS Caremark: Covers Ozempic for diabetes. Mounjaro coverage has expanded. Wegovy coverage limited to plans that specifically include weight management drugs.
- Cigna/Express Scripts: Covers at least one GLP-1 for diabetes on most formularies. Wegovy and Zepbound coverage varies significantly by plan.
- Blue Cross Blue Shield: Varies by state. Some BCBS plans have broad GLP-1 coverage; others are restrictive. Check your specific state BCBS formulary.
- Medicare Part D: Covers Ozempic and Mounjaro for diabetes. Recent legislation has expanded potential coverage for weight management indications, but individual Part D plan formularies vary.
Which GLP-1 Has the Best Chance of Approval?
If your doctor is flexible on which GLP-1 to prescribe, these factors affect approval likelihood:
- Check your formulary first. Your insurer's formulary (drug list) determines which GLP-1 is "preferred." Preferred drugs require lower copays and less prior authorization.
- Diabetes indication has higher approval rates than weight management across all insurers.
- Cardiovascular benefit data strengthens the case for semaglutide (Ozempic/Wegovy) given the SUSTAIN-6 and SELECT trial results showing reduced cardiovascular events.
- Tirzepatide (Mounjaro/Zepbound) has shown superior A1C reduction and weight loss in head-to-head trials (SURMOUNT), which can support appeals when semaglutide is denied.
Appealing a GLP-1 Denial
If your GLP-1 medication is denied, the appeal strategy depends on the denial reason. For step therapy denials, document prior medication trials. For formulary exclusions, request a formulary exception with clinical justification. For medical necessity denials, cite ADA guidelines and cardiovascular benefit data. AppealArmor identifies the specific denial reason and generates the appropriate appeal strategy automatically.
Ready to Fight Your Denial?
AppealArmor generates GLP-1-specific appeals with ADA guidelines, clinical trial citations, formulary exception arguments, and insurer-specific coverage intelligence.
Generate Your Appeal — Free